Monthly Archives: May 2012

PMSI report sees reversal of three-year trend on pharmacy spend The company’s 2011 Annual Drug Trends Report shows decreases in pharmacy costs and utilization based on an analysis of 5.4 million retail and mail-order transactions between 2008 and 2010. The … Continue reading →

Glenmark Gets Licensing Deal Boost Glenmark Pharmaceuticals Ltd. stock got a booster Monday after the company said it has agreed to license out development and commercialization rights of a biologic treatment to France’s Sanofi-Aventis S.A. Shares in the company zoomed … Continue reading →

FDA Approves Merck’s New Drug Victrelis For Treatment Of Hepatitis C The U.S. Food and Drug Administration (FDA) announced late yesterday that it has approved Victrelis for the treatment of hepatitis C. Victrelis (boceprevir), which will be marketed by the … Continue reading →

Takeda says has not agreed to buy Nycomed Takeda, Japan’s largest drugmaker, said on Friday it has not agreed to buy Swiss rival Nycomed, following reports it was in talks to buy the privately held company for more than $12 … Continue reading →

Aurobindo turns billion dollar pharmaceutical company Hyderabad-based Aurobindo Pharma has joined the billion-dollar club of pharma fraternity as the company’s consolidated revenues registered a growth of 22.5% at Rs 4381.5 crore in the financial year ended March 31, 2011 as … Continue reading →

J&J files new Concerta lawsuit against Impax Labs Impax Laboratories Inc. said Friday it received a second patent lawsuit from Johnson & Johnson’s Alza Corp. division related to Impax’s proposed generic version of drug Concerta, which treats the attention deficit … Continue reading →

Georgia joins $44.3 million pharmaceutical settlement Georgia has joined other states and the U.S. government in reaching a $44.3 million settlement with the pharmaceutical manufacturer EMD Serono Inc., the state Attorney General’s Office said Thursday. The agreement settles allegations that … Continue reading →

UPDATE 1-Cephalon profit misses, company likes Teva deal * Q1 adjusted EPS $1.98 vs Street view $2.04 * Revenue $745.1 million * Says Teva offer provides maximum shareholder value NEW YORK, May 3 (Reuters) – Cephalon Inc (CEPH.O), which this … Continue reading →